Details
Stereochemistry | ACHIRAL |
Molecular Formula | Cu |
Molecular Weight | 63.546 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 2 |
SHOW SMILES / InChI
SMILES
[Cu++]
InChI
InChIKey=JPVYNHNXODAKFH-UHFFFAOYSA-N
InChI=1S/Cu/q+2
Molecular Formula | Cu |
Molecular Weight | 63.546 |
Charge | 2 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a84d61a4-8e7f-4be1-aba6-f633b334aafc | http://www.sciencedirect.com/science/article/pii/S0167488912000158http://www.drugfuture.com/chemdata/schweizer-s-reagent.html | http://pubs.acs.org/doi/abs/10.1021/ed062p878?journalCode=jceda8 | http://pubs.acs.org/doi/abs/10.1021/ed019p356http://www.emdmillipore.com/US/en/product/Copper-di-ammonium-Titriplex-solution,MDA_CHEM-105217https://www.ncbi.nlm.nih.gov/pubmed/15704330 | https://www.ncbi.nlm.nih.gov/pubmed/12425037 | https://www.ncbi.nlm.nih.gov/pubmed/1599240 | http://www.certisusa.com/pdf-labels/Kocide3000_label.pdf | http://www.pesticideinfo.org/Detail_Chemical.jsp?Rec_Id=PC33524https://www.ncbi.nlm.nih.gov/pubmed/8556785 | https://www.ncbi.nlm.nih.gov/pubmed/2135524https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=522.518 | http://www.worldofchemicals.com/chemicals/chemical-properties/cupric-glycinate.htmlDOI: 10.1107/s0567740869001725 Retrived from http://scripts.iucr.org/cgi-bin/paper?S0567740869001725https://www.ncbi.nlm.nih.gov/pubmed/16971307https://www3.epa.gov/pesticides/chem_search/ppls/019713-00509-20110705.pdfhttp://www.drugfuture.com/chemdata/tetraamminecopper-sulfate.html | https://cameochemicals.noaa.gov/chemical/3026https://www.ncbi.nlm.nih.gov/pubmed/6526221http://fs1.agrian.com/pdfs/CORE_7.5_Copper_EDTA_Label.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/24106015 | https://www.ncbi.nlm.nih.gov/pubmed/20942456http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500013010.pdfCurator's Comment: description was created based on several sources, including
https://www.copper.org/resources/properties/compounds/other_compounds.html | http://www.vitamins-supplements.org/dietary-minerals/copper.php | https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=bea888b4-9cc6-49da-89e6-5c273b974ed1
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a84d61a4-8e7f-4be1-aba6-f633b334aafc | http://www.sciencedirect.com/science/article/pii/S0167488912000158http://www.drugfuture.com/chemdata/schweizer-s-reagent.html | http://pubs.acs.org/doi/abs/10.1021/ed062p878?journalCode=jceda8 | http://pubs.acs.org/doi/abs/10.1021/ed019p356http://www.emdmillipore.com/US/en/product/Copper-di-ammonium-Titriplex-solution,MDA_CHEM-105217https://www.ncbi.nlm.nih.gov/pubmed/15704330 | https://www.ncbi.nlm.nih.gov/pubmed/12425037 | https://www.ncbi.nlm.nih.gov/pubmed/1599240 | http://www.certisusa.com/pdf-labels/Kocide3000_label.pdf | http://www.pesticideinfo.org/Detail_Chemical.jsp?Rec_Id=PC33524https://www.ncbi.nlm.nih.gov/pubmed/8556785 | https://www.ncbi.nlm.nih.gov/pubmed/2135524https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=522.518 | http://www.worldofchemicals.com/chemicals/chemical-properties/cupric-glycinate.htmlDOI: 10.1107/s0567740869001725 Retrived from http://scripts.iucr.org/cgi-bin/paper?S0567740869001725https://www.ncbi.nlm.nih.gov/pubmed/16971307https://www3.epa.gov/pesticides/chem_search/ppls/019713-00509-20110705.pdfhttp://www.drugfuture.com/chemdata/tetraamminecopper-sulfate.html | https://cameochemicals.noaa.gov/chemical/3026https://www.ncbi.nlm.nih.gov/pubmed/6526221http://fs1.agrian.com/pdfs/CORE_7.5_Copper_EDTA_Label.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/24106015 | https://www.ncbi.nlm.nih.gov/pubmed/20942456http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500013010.pdf
Curator's Comment: description was created based on several sources, including
https://www.copper.org/resources/properties/compounds/other_compounds.html | http://www.vitamins-supplements.org/dietary-minerals/copper.php | https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=bea888b4-9cc6-49da-89e6-5c273b974ed1
Cupric oxide is the oxide of the copper with the chemical formula of CuO. It is used in the ceramic industry for imparting blue, green or red tints in glasses, glazes and enamels. Cupric oxide is also used as a source for copper in food supplements. Copper is an essential nutrient and a normal constituent of the diet in man and animals. The average daily dietary requirement for copper in humans has been estimated at 0.03 mg/kg body weight. Although rare, copper deficiency has been induced by supplemental zinc therapy.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19014916https://www.ncbi.nlm.nih.gov/pubmed/27022258
Curator's Comment: Known to be CNS active in zebrafish. Human data not available.
Originator
Sources: Schweizer, J. Prakt. Chem. 72, 109, 344 (1857).http://pubs.acs.org/doi/abs/10.1021/ja01512a012
Curator's Comment: http://www.drugfuture.com/chemdata/schweizer-s-reagent.html
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1075246 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3861140 |
3.42 µM [Ki] | ||
Target ID: P00450 Gene ID: 1356.0 Gene Symbol: CP Target Organism: Homo sapiens (Human) |
|||
Target ID: Glutathione S-transferase, rat, liver Sources: https://www.ncbi.nlm.nih.gov/pubmed/3008276 |
|||
Target ID: GO:0072593 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8503093 |
|||
Target ID: CHEMBL354 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22098250 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | Unknown Approved UseUnknown |
|||
Preventing | Unknown Approved UseUnknown |
|||
Preventing | Cupric glycinate Approved UseIndications for use. For beef calves and beef cattle for the prevention of copper deficiency, or when labeled for veterinary prescription use, for the prevention and/or treatment of copper deficiency alone or in association with molybdenum toxicity. |
|||
Primary | COPPER•MAX Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Preventing | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Diagnostic | Unknown Approved UseUnknown |
|||
Preventing | COPPER Approved UseCopper 0.4 mg/mL (Cupric Chloride Injection, USP) is indicated for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN). Administration helps to maintain copper serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms. |
|||
Preventing | COPINOX Approved UseCopinox 4g is indicated for the prevention and treatment of copper deficiency in cattle and sheep. |
PubMed
Title | Date | PubMed |
---|---|---|
A spectroscopic and thermoanalytical study of the mineral hoganite. | 2007 May |
|
Enhanced copper release from pipes by alternating stagnation and flow events. | 2007 Nov 1 |
|
Synthesis and structural investigation of mono- and polynuclear copper complexes of 4-ethyl-1-(pyridin-2-yl) thiosemicarbazide. | 2008 Nov 1 |
|
Zinc prevents the copper-induced damage of cultured astrocytes. | 2010 Oct |
|
Expeditious synthesis of phenanthrenes via CuBr2-catalyzed coupling of terminal alkynes and N-tosylhydrazones derived from o-formyl biphenyls. | 2011 Oct 7 |
|
Evaluation of topically applied copper(II) oxide nanoparticle cytotoxicity in human skin organ culture. | 2013 Feb |
|
Cytotoxicity in the age of nano: the role of fourth period transition metal oxide nanoparticle physicochemical properties. | 2013 Nov 25 |
|
Interference of CuO nanoparticles with metal homeostasis in hepatocytes under sub-toxic conditions. | 2014 |
|
Unusual 4-arsonoanilinium cationic species in the hydrochloride salt of (4-aminophenyl)arsonic acid and formed in the reaction of the acid with copper(II) sulfate, copper(II) chloride and cadmium chloride. | 2017 Apr 1 |
|
Ultrasonic energy enhanced the efficiency of advance extraction methodology for enrichment of trace level of copper in serum samples of patients having neurological disorders. | 2017 Jul |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a84d61a4-8e7f-4be1-aba6-f633b334aafc
Curator's Comment: Veterinary drug
Copper 0.4 mg/mL (Cupric Chloride Injection) contains 0.4 mg copper/mL and is administered intravenously only after dilution. The additive should be diluted in a volume of fluid not less than 100 mL. For the adult receiving total parenteral nutrition, the suggested additive dosage is 0.5 to 1.5 mg copper/day (1.25 to 3.75 mL/day). For pediatric patients, the suggested additive dosage is 20 mcg copper/kg/day (0.05 mL/kg/day). Infants weighing less than 1500 gm may have increased requirements because of their low body reserves and increased requirements for growth.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27726061
Human Endometrial Stromal Cells were treated with non-toxic concentrations of copper ions (0-250 uM). mRNA expressions of insulin-like growth factor binding protein (IGFBP-1), prolactin (PRL), Mn-SOD, and FOXO1 were down-regulated during decidualization following the treatments with 100 or 250 uM copper ions. Meanwhile, the amount of malonaldehyde in the supernatant of cells was increased.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 17:11:29 UTC 2022
by
admin
on
Fri Dec 16 17:11:29 UTC 2022
|
Record UNII |
8CBV67279L
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C68249
Created by
admin on Fri Dec 16 17:11:30 UTC 2022 , Edited by admin on Fri Dec 16 17:11:30 UTC 2022
|
||
|
FDA ORPHAN DRUG |
771520
Created by
admin on Fri Dec 16 17:11:30 UTC 2022 , Edited by admin on Fri Dec 16 17:11:30 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
15158-11-9
Created by
admin on Fri Dec 16 17:11:30 UTC 2022 , Edited by admin on Fri Dec 16 17:11:30 UTC 2022
|
PRIMARY | |||
|
8CBV67279L
Created by
admin on Fri Dec 16 17:11:30 UTC 2022 , Edited by admin on Fri Dec 16 17:11:30 UTC 2022
|
PRIMARY | |||
|
1427198
Created by
admin on Fri Dec 16 17:11:30 UTC 2022 , Edited by admin on Fri Dec 16 17:11:30 UTC 2022
|
PRIMARY | RxNorm | ||
|
DTXSID40934294
Created by
admin on Fri Dec 16 17:11:30 UTC 2022 , Edited by admin on Fri Dec 16 17:11:30 UTC 2022
|
PRIMARY | |||
|
27099
Created by
admin on Fri Dec 16 17:11:30 UTC 2022 , Edited by admin on Fri Dec 16 17:11:30 UTC 2022
|
PRIMARY | |||
|
29036
Created by
admin on Fri Dec 16 17:11:30 UTC 2022 , Edited by admin on Fri Dec 16 17:11:30 UTC 2022
|
PRIMARY | |||
|
C68251
Created by
admin on Fri Dec 16 17:11:30 UTC 2022 , Edited by admin on Fri Dec 16 17:11:30 UTC 2022
|
PRIMARY | |||
|
8CBV67279L
Created by
admin on Fri Dec 16 17:11:30 UTC 2022 , Edited by admin on Fri Dec 16 17:11:30 UTC 2022
|
PRIMARY | |||
|
DB09130
Created by
admin on Fri Dec 16 17:11:30 UTC 2022 , Edited by admin on Fri Dec 16 17:11:30 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
LIGAND->TARGET |
Scientific Literature
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |